PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders.
Our lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. PB2452 was exclusively licensed from MedImmune, the global biologics research and development arm of AstraZeneca, for global development and commercialization by PhaseBio. We recently completed a Phase 1 clinical trial of PB2452 in healthy subjects and published the results of the trial in the New England Journal of Medicine.
Our second product candidate, PB1046, is being developed as a once-weekly novel treatment for pulmonary arterial hypertension (PAH). PB1046 is a subcutaneously-injected, sustained release analogue of the native human peptide, vasoactive intestinal peptide. PB1046 utilizes our proprietary half-life extending elastin-like polypeptide (ELP) technology. We are currently conducting a Phase 2b clinical trial of PB1046 in patients with PAH.
Our proprietary ELP technology platform uses recombinant elastin-like polypeptide biopolymers to extend the circulating half-life of proteins and peptides and provide a sustained-release mechanism, resulting in exposure of active molecules for periods of a week or longer from a single subcutaneous injection. We believe that our ELP technology enhances solubility, stability and bioavailability, provides extended drug exposure and creates product candidates that are straightforward to manufacture and easy to administer.